144 related articles for article (PubMed ID: 24636526)
1. Use of the Functional Assessment of Cancer Therapy--anemia in persons with myeloproliferative neoplasm-associated myelofibrosis and anemia.
Tefferi A; Hudgens S; Mesa R; Gale RP; Verstovsek S; Passamonti F; Cervantes F; Rivera C; Tencer T; Khan ZM
Clin Ther; 2014 Apr; 36(4):560-6. PubMed ID: 24636526
[TBL] [Abstract][Full Text] [Related]
2. A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence.
Tefferi A; Al-Ali HK; Barosi G; Devos T; Gisslinger H; Jiang Q; Kiladjian JJ; Mesa R; Passamonti F; McMullin MF; Ribrag V; Schiller G; Vannucchi AM; Zhou D; Reiser D; Zhong J; Gale RP
Leukemia; 2017 Apr; 31(4):896-902. PubMed ID: 27773929
[TBL] [Abstract][Full Text] [Related]
3. Pomalidomide is active in the treatment of anemia associated with myelofibrosis.
Tefferi A; Verstovsek S; Barosi G; Passamonti F; Roboz GJ; Gisslinger H; Paquette RL; Cervantes F; Rivera CE; Deeg HJ; Thiele J; Kvasnicka HM; Vardiman JW; Zhang Y; Bekele BN; Mesa RA; Gale RP; Kantarjian HM
J Clin Oncol; 2009 Sep; 27(27):4563-9. PubMed ID: 19652059
[TBL] [Abstract][Full Text] [Related]
4. Improvement of the hematologic toxicities of ruxolitinib in patients with MPN-associated myelofibrosis using a combination of thalidomide, stanozolol and prednisone.
Duan M; Zhou D
Hematology; 2019 Dec; 24(1):516-520. PubMed ID: 31242816
[No Abstract] [Full Text] [Related]
5. Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia.
Daver N; Shastri A; Kadia T; Newberry K; Pemmaraju N; Jabbour E; Zhou L; Pierce S; Cortes J; Kantarjian H; Verstovsek S
Leuk Res; 2014 Sep; 38(9):1126-9. PubMed ID: 25047979
[TBL] [Abstract][Full Text] [Related]
6. [Transfusion independence achieved with pomalidomide therapy in a patient with primary myelofibrosis].
Edahiro Y; Gotoh A; Inano T; Tsutsui M; Tsukune Y; Yasuda H; Komatsu N
Rinsho Ketsueki; 2018; 59(3):323-325. PubMed ID: 29618692
[TBL] [Abstract][Full Text] [Related]
7. Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide.
Chowdhury O; O'Sullivan J; Barkas N; Wang G; Buck G; Hamblin A; Tefferi A; Al-Ali HK; Barosi G; Devos T; Gisslinger H; Jiang Q; Kiladjian JJ; Mesa R; Passamonti F; Ribrag V; Schiller G; Vannucchi AM; Zhou D; McMullin MF; Zhong J; Gale RP; Mead AJ;
Leukemia; 2021 Apr; 35(4):1197-1202. PubMed ID: 32770086
[No Abstract] [Full Text] [Related]
8. Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis.
Schlenk RF; Stegelmann F; Reiter A; Jost E; Gattermann N; Hebart H; Waller C; Hochhaus A; Platzbecker U; Schafhausen P; Blau IW; Verbeek W; Heidel FH; Werner M; Kreipe H; Teleanu V; Benner A; Döhner H; Grießhammer M; Döhner K
Leukemia; 2017 Apr; 31(4):889-895. PubMed ID: 27774990
[TBL] [Abstract][Full Text] [Related]
9. Ruxolitinib combined with prednisone, thalidomide and danazol in patients with myelofibrosis: Results of a pilot study.
Qu S; Xu Z; Qin T; Li B; Pan L; Chen J; Yan X; Wu J; Zhang Y; Zhang P; Gale RP; Xiao Z
Hematol Oncol; 2022 Oct; 40(4):787-795. PubMed ID: 35609279
[TBL] [Abstract][Full Text] [Related]
10. Thalidomide plus prednisone with or without danazol therapy in myelofibrosis: a retrospective analysis of incidence and durability of anemia response.
Luo X; Xu Z; Li B; Qin T; Zhang P; Zhang H; Fang L; Pan L; Hu N; Qu S; Zhang Y; Huang G; Peter Gale R; Xiao Z
Blood Cancer J; 2018 Jan; 8(1):9. PubMed ID: 29335406
[TBL] [Abstract][Full Text] [Related]
11. [Comparison of low-dose thalidomide and prednisone combined with or without danazol for the treatment of primary myelofibrosis-associated anemia].
Xu J; Xu Z; Qin T; Li B; Fang L; Zhang H; Hu N; Pan L; Qu S; Zhang Y; Xiao Z
Zhonghua Xue Ye Xue Za Zhi; 2014 Aug; 35(8):698-702. PubMed ID: 25152115
[TBL] [Abstract][Full Text] [Related]
12. Modest activity of pomalidomide in patients with myelofibrosis and significant anemia.
Daver N; Shastri A; Kadia T; Quintas-Cardama A; Jabbour E; Konopleva M; O'Brien S; Pierce S; Zhou L; Cortes J; Kantarjian H; Verstovsek S
Leuk Res; 2013 Nov; 37(11):1440-4. PubMed ID: 23890523
[TBL] [Abstract][Full Text] [Related]
13. Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis.
Quintás-Cardama A; Kantarjian HM; Manshouri T; Thomas D; Cortes J; Ravandi F; Garcia-Manero G; Ferrajoli A; Bueso-Ramos C; Verstovsek S
J Clin Oncol; 2009 Oct; 27(28):4760-6. PubMed ID: 19720904
[TBL] [Abstract][Full Text] [Related]
14. Effect of Red Blood Cell Transfusion Dependence on the Natural History of Myeloproliferative Neoplasm-Associated Myelofibrosis.
Bartoszko J; Panzarella T; Lau A; Schimmer A; Schuh A; Shanavas M; Yee K; Gupta V
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):e151-6. PubMed ID: 26566925
[TBL] [Abstract][Full Text] [Related]
15. A phase-2 trial of low-dose pomalidomide in myelofibrosis.
Begna KH; Mesa RA; Pardanani A; Hogan WJ; Litzow MR; McClure RF; Tefferi A
Leukemia; 2011 Feb; 25(2):301-4. PubMed ID: 21052089
[TBL] [Abstract][Full Text] [Related]
16. Long-term results of prednisone treatment for the anemia of myelofibrosis.
Hernández-Boluda JC; Martínez-Trillos A; García-Gutiérrez V; Ferrer-Marín F; Xicoy B; Alvarez-Larrán A; Kerguelen A; Barba P; Gómez M; Herrera JC; Correa JG; Cervantes F
Leuk Lymphoma; 2016; 57(1):120-4. PubMed ID: 25944376
[TBL] [Abstract][Full Text] [Related]
17. Thalidomide in myelofibrosis with myeloid metaplasia: a pooled-analysis of individual patient data from five studies.
Barosi G; Elliott M; Canepa L; Ballerini F; Piccaluga PP; Visani G; Marchetti M; Pozzato G; Zorat F; Tefferi A
Leuk Lymphoma; 2002 Dec; 43(12):2301-7. PubMed ID: 12613516
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic approaches in myelofibrosis.
Barosi G; Rosti V; Vannucchi AM
Expert Opin Pharmacother; 2011 Jul; 12(10):1597-611. PubMed ID: 21457082
[TBL] [Abstract][Full Text] [Related]
19. The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: An analysis by the MPN QOL International Study Group.
Geyer HL; Andreasson B; Kosiorek HE; Dueck AC; Scherber RM; Martin KA; Butler KA; Harrison CN; Radia DH; Cervantes F; Kiladjian JJ; Reiter A; Birgegard G; Passamonti F; Senyak Z; Vannucchi AM; Paoli C; Xiao Z; Samuelsson J; Mesa RA
Cancer; 2016 Jun; 122(12):1888-96. PubMed ID: 27070130
[TBL] [Abstract][Full Text] [Related]
20. Clinical characteristics and symptom burden of Thai myeloproliferative neoplasm patients.
Cherdchoo N; Polprasert C; Rojnuckarin P; Kongkiatkamon S
Hematology; 2023 Dec; 28(1):2280731. PubMed ID: 37942783
[No Abstract] [Full Text] [Related]
[Next] [New Search]
